Archive: 11/04/2016

Venclexta approved for specific genetic blood cancer

(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.

page 1 from 11